Eosinophilic fasciitis is a connective tissue disorder characterized by inflammation of the muscle fasciae, which is very rare in children. In juvenile-onset eosinophilic fasciitis (JEF), there may be severe joint involvement and skin manifestations may be less prevalent than in adults. It represents an important differential diagnosis of both juvenile-onset systemic sclerosis and localized scleroderma, and the correct classification of these patients is necessary to define a targeted diagnostic-therapeutic pathway. The diagnostic criteria proposed for eosinophilic fasciitis in the adult population (Pinal-Fernandez et al. 20145; JInnin M 20186) do not necessarily require confirmation by skin biopsy, currently the "gold standard," which is an invasive procedure for pediatric patients; however, these criteria have never been directly applied to the pediatric population. From a therapeutic point of view, the combination of glucocorticoids and methotrexate is recommended for both adults and pediatric patients, but the data supporting this treatment in children are very limited, and there are no studies comparing the therapeutic approaches currently in use in pediatrics. Finally, there are no studies in the literature documenting the long-term prognosis of these patients in terms of functional limitations, quality of life, or complications related to the disease or treatments.
Study Type
OBSERVATIONAL
Enrollment
20
University of Alabama at Birmingham
Birmingham, Alabama, United States
RECRUITINGSUNY Upstate Pediatric Rheumatology
Syracuse, New York, United States
RECRUITINGChildren's Hospital Zagreb
Zagreb, Croatia
RECRUITINGMeyer Children's Hospital IRCCS
Florence, FI, Italy
RECRUITINGIuliu Hatieganu University of Medicine and Pharmacy
Cluj-Napoca, Romania
RECRUITINGAstrid Lindgren Children's Hospital
Solna, Stockholm County, Sweden
RECRUITINGClinical and laboratory features
Describe the clinical and laboratory features at presentation and during follow-up, including the extent of skin involvement and extracutaneous manifestations, of patients diagnosed with JEF.
Time frame: 2025-2027
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.